Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) of >6 months

  • Martin Bögemann (Contributor)
  • Neal Shore (Contributor)
  • Tammela, T. (Contributor)
  • Albertas Ulys (Contributor)
  • Egils Vjaters (Contributor)
  • Sergey Polyakov (Contributor)
  • Mindaugas Jievaltas (Contributor)
  • Murilo Luz (Contributor)
  • Boris Alekseev (Contributor)
  • Iris Kuss (Contributor)
  • Marie-Aude Le Berre (Contributor)
  • Amir Snapir (Contributor)
  • Toni Sarapohja (Contributor)
  • Karim Fizazi (Contributor)

Aktiviteetti: Konferenssiesitelmä


Contributors: Bögemann, Martin Shore, Neal Tammela, Teuvo Ulys, Albertas Vjaters, Egils Polyakov, Sergey Jievaltas, Mindaugas Luz, Murilo Alekseev, Boris Kuss, Iris Le Berre, Marie-Aude Snapir, Amir Sarapohja, Toni Fizazi, Karim
Aikajakso17 heinäk. 2020
Tapahtuman otsikko35th Annual EAU Congress - Virtual (EAU20V)
Tapahtuman tyyppiOther
Tunnustuksen arvoInternational